Spotlight Session - RWE Collaborative

(A41) Cardiovascular Risk and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors: A Nationwide Comparative Effectiveness Research Study

(A42) Case studies of FDA recently approved product applications using real-world evidence - What are the attributes of studies that support effectiveness determinations?

(A43) Decreased Venous Thromboembolic Risk of Estradiol Valerate/Dienogest COCs Compared to First-line COCs Containing Ethinyl Estradiol/Levonorgestrel: Pooled Analysis in a Large Real-World User Population

(A44) Lessons Learned from the Development of Machine Learning Models to Estimate Validated Measures Using Real-World Data for Four Chronic Conditions

(A45) Machine Learning to Predict Successful Treatment of Atrial Fibrillation by Medical Devices Using Digital Data Linked to EHR Data

(A46) Progression to ESRD Among White, Black and Hispanic Diabetic Kidney Disease Patients: Real-World Evidence from Multiple Linked Claims Databases

(A47) Use and contribution of registries in registry-based randomized clinical trials: a review

(A48) Use of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification in Europe: a DARWIN-EU® multinational network cohort study (EUPAS103381)